SK Life Science Publishes Updated Real-World Experience on Cenobamate in Epilepsia Based on Recent 100,000 Patient Exposure Milestone

Posted on by

PARAMUS, N.J., March 13, 2024 /PRNewswire/ — SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, today announced an update on the use of cenobamate, an…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.